10x Genomics(US:TXG) Yahoo Financeยท2025-11-07 21:06Core Insights - 10x Genomics reported third-quarter financial results that exceeded Wall Street expectations, leading to a 14.3% increase in share price [1][2] - The company projected fourth-quarter revenue between $154 million and $158 million, surpassing analysts' forecasts, indicating strong confidence in future performance [2] Financial Performance - For Q3, 10x Genomics generated revenue of $149 million, above the consensus estimate of $142.4 million [2] - The loss per share was $0.22, which was narrower than the anticipated loss of $0.28 [2] - The stock closed at $15.25, reflecting a 17.4% increase from the previous close [3] Market Reaction - The shares of 10x Genomics have shown extreme volatility, with 48 moves greater than 5% in the past year, indicating significant market impact from recent news [4] - The previous notable stock movement occurred 18 days prior, when the stock rose 6% after BofA Securities maintained a "Buy" rating while lowering the price target from $15.00 to $13.00 [5] Investment Performance - Year-to-date, 10x Genomics shares are up 7.5%, trading close to a 52-week high of $16.47 [6] - An investment of $1,000 in 10x Genomics shares five years ago would now be valued at $113.74 [6]